Zachery Carter
HomeProductsFAQSign In
© 2026 Zachery Carter. All rights reserved.
ProductsFAQadmin@mypeptide.net(850) 384-0430Sign In
Legal
MyPeptide Privacy PolicyShipping and Returns PolicyMyPeptide Terms and Conditions
FDA DISCLAIMER

Statements made regarding our products have not been evaluated by the U.S. Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. Products are not intended to diagnose, treat, cure, or prevent any disease. Information presented on this website is not a substitute for, or alternative to, information from a qualified health care practitioner. Please consult a licensed health care professional regarding any potential interactions or complications before using any product. This notice is required under the Federal Food, Drug, and Cosmetic Act.

HomeShopSign In

Researcher verification

MyPeptide sells research peptides exclusively to qualified researchers and laboratories for in vitro and laboratory use. Please confirm before continuing.

By proceeding you affirm the statements above are true. Products are not for human or veterinary use, not for use in diagnostic procedures, and have not been evaluated by the U.S. Food and Drug Administration.

© 2026 MyPeptide.net all rights reserved
Back to catalog
2x Blend: CJC-1295 No DAC (5 mg) + Ipamorelin (5 mg)
Growth Hormone Research
Research Use Only — Not for Human or Veterinarian Administration

2x Blend: CJC-1295 No DAC (5 mg) + Ipamorelin (5 mg)

A synergistic GH secretagogue blend combining CJC-1295 (No DAC) with Ipamorelin for dual-pathway GH axis research — GHRH receptor activation plus ghrelin receptor (GHS-R) stimulation.

Select size

lyophilized
$59.00/ 2X Blend: CJC-1295 No DAC (5 mg) / Ipamorelin (5 mg)
Certificate of Analysis — 2x Blend: CJC-1295 No DAC (5 mg) + Ipamorelin (5 mg)Certificate of AnalysisThird-party HPLC lab report · opens PDF

For laboratory and research use only. Not for human or veterinary use.

Mechanism of Action

CJC-1295 activates GHRH receptors; Ipamorelin selectively stimulates GHS-R1a with minimal cortisol/prolactin elevation in research models. Combined protocols explore synergistic GH pulse amplification.

Research Applications

  • Dual secretagogue GH axis research
  • Comparative single vs. blend protocol studies
  • GHS-R and GHRH receptor interaction assays

Specifications

sequenceCJC-1295 + Ipamorelin blend
molecular WeightBlend — see component COAs
appearanceWhite lyophilized powder

Reconstitution (Laboratory)

Reconstitute with bacteriostatic water. Confirm component masses via COA.

Storage & Handling

Lyophilized: 2–8 °C. Reconstituted: refrigerate.

Quality Assurance

Every lot undergoes independent third-party HPLC purity analysis, mass spectrometry identity confirmation, and endotoxin testing (<0.5 EU/mg). Certificate of Analysis (COA) is stored against the SKU lot number and available through your research account portal.

Sources & References

  1. 1.Raun K, et al. Ipamorelin, a new growth-hormone-releasing peptide, potently and selectively. J Endocrinol. 1998. · PubMed →
  2. 2.Teichman SL, et al. CJC-1295 pharmacokinetics. J Clin Endocrinol Metab. 2006. · PubMed →